- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...

1910's CANDID-CNS™ AI model has been published in the Journal of Chemical Information and Modeling (JCIM), a journal of the American Chemical Society. CANDID-CNS™ is the new state-of-the-art AI model ...

CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. CANDID-CNS™ distinguishes CNS penetrant ...

COYA 303 is an investigational proprietary combination of LD-IL-2 and GLP-1RA for subcutaneous administration, under development for the treatment of diseases, including Alzheimer's Disease, driven by ...

Figure 1: Prof. LIU Kai (first right, front row) from the Division of Life Science and Department of Chemical and Biological Engineering and his research team, alongside with Prof. WANG Yiwen (first ...